CTRI/2022/02/040539CompletedPhase 3
Comparison of 6 months Isoniazid v/s 3 months Isoniazid - Rifampicin Therapy for Prevention of Tuberculosis in Children Suffering from Latent Tuberculosis Infection - An Open Label Randomized Controlled Trial
DR SHIVANGI SINHA0 sites64 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 64
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •children (6-14years)with LTBI living with sputum smear positive adult TB patients undergoing DOTS
Exclusion Criteria
- •children in contact with adults having multidrug resistant TB (MDR-TB) or Extensively drug resistanT TB(XDR-TB).
Investigators
Similar Trials
Not yet recruiting
Phase 3
To compare number of healthy household contacts aged less than 5 years developing Tuberculosis disease after receiving treatment with 3 months isoniazid and rifampicin versus 6 months isoniazidCTRI/2023/05/052273Areej bano
Completed
Phase 3
A comparison between the effect of Isoniazid together with Misoprostol and Misoprostol on abortion in the first three months of pregnancy.IRCT20190819044561N1Iran University of Medical Sciences80
Not yet recruiting
Phase 2
Evaluating effectiveness of therapy with topical isoniazid in melasmamelasma.Other melanin hyperpigmentationL81.4IRCT20211125053175N1Kerman University of Medical Sciences20
Completed
Not Applicable
The effect of duration of treatment with valganciclovir in children with renal transplantatioCondition 1: renal failure. Condition 2: CMV infection.Acute renal failureOther and unspecified infectious diseasesIRCT2015021321062N1Iran University of Medical Sciences86
Completed
Not Applicable
STUDY OF EFFECTIVENESS AND TOLERABILITY OF ISONIAZIDE / RIFAPENTIN ONCE A WEEK FOR THREE MONTHS VERSUS ISONIAZIDE DAILY FOR NINE MONTHS FOR THE TREATMENT OF A LATENT INFECTION WITH TUBERCULOSIS-B24 Unspecified human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseB24PER-016-09Institutos Nacionales de Salud (NIH, siglas en ingles) de los Estados Unidos de America,32